AFT Pharmaceuticals (NZSE:AFT) Common Stock: NZ$78.2 Mil (As of Mar. 2026)


NZSE:AFT AFT Pharmaceuticals Ltd NZSE:AFT
95 GF Score
Price NZ$3.71
GF Value NZ$4.17
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Common Stock?

AFT Pharmaceuticals NZSE:AFT +0.27% 95 Common Stock is NZ$78.2 Mil as of Mar. 2026. GuruFocus rates NZSE:AFT with a GF Score™ of 95/100 and a GF Value™ of NZ$4.17 (Modestly Undervalued). The stock has 3 warning signs investors should review.

AFT Pharmaceuticals's quarterly common stock stayed the same from Mar. 2025 (NZ$78.2 Mil) to Sep. 2025 (NZ$78.2 Mil) and stayed the same from Sep. 2025 (NZ$78.2 Mil) to Mar. 2026 (NZ$78.2 Mil).

AFT Pharmaceuticals's annual common stock stayed the same from Mar. 2024 (NZ$78.2 Mil) to Mar. 2025 (NZ$78.2 Mil) and stayed the same from Mar. 2025 (NZ$78.2 Mil) to Mar. 2026 (NZ$78.2 Mil).

AFT Pharmaceuticals Common Stock Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Common Stock Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.61 78.24 78.24 78.24 78.24

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.24 78.24 78.24 78.24 78.24
NZSE:AFT
95GF Score
AFT Pharmaceuticals Ltd NZSE:AFT
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of NZ$78.2 Mil mean?
AFT Pharmaceuticals (NZSE:AFT) has a Common Stock of NZ$78.2 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Common Stock too high?
AFT Pharmaceuticals' current Common Stock is NZ$78.2 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Common Stock compare to ZTS and UTHR?
AFT Pharmaceuticals' Common Stock of NZ$78.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Common Stock is NZ$78.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Modestly Undervalued. The stock's GF Value™ is NZ$4.17, compared to a current price of NZ$3.71 — trading 11% below its estimated fair value. The current Common Stock is NZ$78.2 Mil. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current Common Stock is NZ$78.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of NZ$3.71 is trading 11% below its estimated GF Value™ of NZ$4.17. GuruFocus considers AFT Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NZSE:AFT:

  • Common Stock: NZ$78.2 Mil
  • GF Value™: NZ$4.17 vs. price of NZ$3.71 (11% below fair value)
  • GF Score™: 95/100 with 3 warning signs

No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFP:Australia
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score

Get the complete analysis for NZSE:AFT

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$3.71
Price
NZ$4.17
GF Value